Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, non-interventional cohort study combining retrospective data from about 500 patients diagnosed with extranodal NK/T-cell lymphoma and a prospective group of about 1,000 newly diagnosed patients with related EBV-positive T/NK-cell diseases. The retrospective cohort collects clinical information, while the prospective cohort collects clinical data plus standardized blood samples and optional tumor tissue for biomarker analyses. Treatments are determined by physicians in routine practice, and researchers will analyze associations between clinical features, biomarkers, and outcomes such as response, relapse, and long-term survival. The study aims to develop integrated clinical-molecular insights to improve prognostication and care for these heterogeneous EBV-driven conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria.
* For the retrospective cohort: diagnosis of extranodal NK/T-cell lymphoma between January 1, 2017 and December 31, 2025 at a participating center.
* For the prospective cohort: diagnosis between June 1, 2026 and December 31, 2030 of one of the following:
* Extranodal NK/T-cell lymphoma;
* Aggressive NK-cell leukemia;
* Systemic chronic active Epstein-Barr virus disease of T/NK-cell type; or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.
* Availability of essential diagnostic, staging, and treatment information.
* For the prospective cohort: written informed consent and successful collection of the protocol-required baseline peripheral blood specimen.

Exclusion Criteria:

* For the retrospective cohort: no usable survival follow-up information, inability to confirm survival status, or inability to calculate the principal survival outcomes.
* For the prospective cohort: unwillingness or inability to participate in protocol-defined longitudinal clinical follow-up.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Rong Tao, MD
• Email: hkutao@hotmail.com
• Phone: 008621-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Frontline immunotherapy versus chemotherapy induction for advanced Extranodal NK/T-cell lymphoma, followed by autologous stem cell transplant

  This study tests whether starting with immunotherapy plus targeted drugs is more effective than standard chemotherapy to help patients with advanced extranodal NK/T‑cell lymphoma, then all patients who reach a strict remission proceed to autologous stem cell transplantation.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07678229

• Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma

  This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07502768

• Treatment for untreated extranodal NK/T-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with untreated extranodal NK/T-cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06824883

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Evaluating the safety of PPMX-T003 for aggressive NK-cell leukemia

  This study is testing a new drug called PPMX-T003 to see if it is safe and effective for people with aggressive NK-cell leukemia.

  Recruiting Phase 1/2 Hiroshima University Hospital · Hiroshima, Hiroshima · NCT05863234

• Evaluating DR-01 for treating specific types of lymphomas

  This study is testing a new treatment called DR-01 to see if it can safely help adults with certain types of lymphomas feel better and fight their cancer.

  Recruiting at 36 sites Phase 1/2 Dren Bio · Birmingham, Alabama and 36 other locations · NCT05475925

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.